Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926520 · ClinicalTrials.gov registry record · NA
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
A NA study of Alzheimer Dementia and Agitation,Psychomotor, sponsored by Brent Forester.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT03926520: Recruiting NA study of Alzheimer Dementia and Agitation,Psychomotor, sponsored by Brent Forester.
NCT03926520 is a NA study of Alzheimer Dementia and Agitation,Psychomotor that is actively recruiting participants, run by Brent Forester. The registered enrollment target is 50 participants, above the 42-participant average among 8 other Alzheimer Dementia trials with a reported enrollment target (19% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926520, a NA study of Alzheimer Dementia and Agitation,Psychomotor, is actively recruiting participants, sponsored by Brent Forester.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.
Primary Outcome
The CMAI measures the efficacy of ECT+UC in reducing severe agitation in AD subjects. The CMAI is a 29-item scale with each item ranging from 1-7 in frequency with 7 being the highest and therefore worst outcome.
Conditions Studied
Interventions
- DEVICE Electroconvulsive Therapy (ECT)
Study Locations (5)
Georgia
- Emory Healthcare - Atlanta
Massachusetts
- McLean Hospital - Belmont
Michigan
- Pine Rest Christian Mental Health Services - Grand Rapids
Minnesota
- Mayo Clinic - Rochester
New York
- Northwell Health - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2025-05-31 |
| Phase | NA |
What NCT03926520 shows while recruiting
NCT03926520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, above the 42-participant average among 8 other Alzheimer Dementia trials with a reported enrollment target (19% higher).
The record links to 2 conditions, with Alzheimer Dementia appearing as the primary indexed condition, and to 1 intervention - of which Electroconvulsive Therapy (ECT) is the first listed.
NCT03926520 lists 5 locations in 5 states (Georgia, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT03926520 about?
NCT03926520 is a clinical study titled "Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)". This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerabi...
What is the current status of trial NCT03926520?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2021-01-28. Estimated completion is 2025-05-31.
What conditions does trial NCT03926520 study?
This clinical trial studies the following conditions: Alzheimer Dementia, Agitation,Psychomotor.
What interventions are being tested in trial NCT03926520?
The interventions under investigation include: Electroconvulsive Therapy (ECT) (DEVICE).
Who is sponsoring clinical trial NCT03926520?
This trial is sponsored by Brent Forester, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03926520 being conducted?
This trial has 5 study locations across Georgia, Massachusetts, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03926520's enrollment target sits among peer trials
50 4th of 8 higher than 5 of 8 other Alzheimer Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
RECRUITING · NA
-
Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
ACTIVE NOT RECRUITING · NA
-
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease
ACTIVE NOT RECRUITING · NA
-
Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers
COMPLETED · NA
-
The Senior Companion Program Plus
COMPLETED · NA
-
Innate Immunity Stimulation Via TLR9 in Early AD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI